News Heart hope for Heartseed/Novo Nordisk HS-001 cell therapy Heartseed & Novo Nordisk say a patient has been successfully dosed with cell therapy HS-001.
News Novo Nordisk crowns cell therapy pipeline with $598m Heartse... Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
